Abstract:We describe closure of an atrial septal defect in a symptomatic 4.6 kg child with the HELEX Septal Occluder (W.L. Gore and Associates, Flagstaff, AZ) via transhepatic approach. Technical considerations are discussed.
“…The transhepatic approach has also been described for atrial septal defect occlusion in small infants, including using the HELEX Septal Occluder in a 4.9-kg patient. 5 The potential advantage is that the delivery catheter approaches the atrial septal defect in a more perpendicular manner and may allow the left atrial disc to deploy more parallelly to the atrial septum; however, we ultimately felt that using the femoral venous approach was feasible and safe. We did note in both patients that during deployment the atrial septum and device were pulled caudal and repositioned upon setting the locking loop; however, this did not result in any haemodynamic instability or arrhythmias.…”
Section: Discussionmentioning
confidence: 99%
“…We did not have any difficulty achieving haemostasis from the venous puncture site upon completion of the procedure, and neither patient had any evidence of venous occlusion or venous stasis in the lower extremity during follow-up. The transhepatic approach has also been described for atrial septal defect occlusion in small infants, including using the HELEX Septal Occluder in a 4.9-kg patient 5 . The potential advantage is that the delivery catheter approaches the atrial septal defect in a more perpendicular manner and may allow the left atrial disc to deploy more parallelly to the atrial septum; however, we ultimately felt that using the femoral venous approach was feasible and safe.…”
Children with a secundum atrial septal defect are usually asymptomatic and are referred for elective closure after 3-4 years of age; however, in premature infants with chronic lung disease, bronchopulmonary dysplasia, or pulmonary hypertension, increased pulmonary blood flow secondary to a left-to-right atrial shunt, may exacerbate their condition. Closure of the atrial septal defect in these patients can result in significant clinical improvement. We report the cases of two premature infants with chronic lung disease, who underwent atrial septal defect closure with the Gore HELEX Septal Occluder and discuss the technical aspects of using the device in these patients and their clinical outcomes.
“…The transhepatic approach has also been described for atrial septal defect occlusion in small infants, including using the HELEX Septal Occluder in a 4.9-kg patient. 5 The potential advantage is that the delivery catheter approaches the atrial septal defect in a more perpendicular manner and may allow the left atrial disc to deploy more parallelly to the atrial septum; however, we ultimately felt that using the femoral venous approach was feasible and safe. We did note in both patients that during deployment the atrial septum and device were pulled caudal and repositioned upon setting the locking loop; however, this did not result in any haemodynamic instability or arrhythmias.…”
Section: Discussionmentioning
confidence: 99%
“…We did not have any difficulty achieving haemostasis from the venous puncture site upon completion of the procedure, and neither patient had any evidence of venous occlusion or venous stasis in the lower extremity during follow-up. The transhepatic approach has also been described for atrial septal defect occlusion in small infants, including using the HELEX Septal Occluder in a 4.9-kg patient 5 . The potential advantage is that the delivery catheter approaches the atrial septal defect in a more perpendicular manner and may allow the left atrial disc to deploy more parallelly to the atrial septum; however, we ultimately felt that using the femoral venous approach was feasible and safe.…”
Children with a secundum atrial septal defect are usually asymptomatic and are referred for elective closure after 3-4 years of age; however, in premature infants with chronic lung disease, bronchopulmonary dysplasia, or pulmonary hypertension, increased pulmonary blood flow secondary to a left-to-right atrial shunt, may exacerbate their condition. Closure of the atrial septal defect in these patients can result in significant clinical improvement. We report the cases of two premature infants with chronic lung disease, who underwent atrial septal defect closure with the Gore HELEX Septal Occluder and discuss the technical aspects of using the device in these patients and their clinical outcomes.
“…Percutaneous femoral venous access is widely accepted as the standard approach for transcatheter ASD closure. However, this approach tends to be abandoned when interruption of the IVC is encountered, in favor of transjugular access [4, 5] or transhepatic puncture [6–11]. There has only been one previous publication describing successful transfemoral device closure of a small ASD in a case of interrupted IVC in an adult [12].…”
ErratumErratum: Metso S, Auvinen A, Huhtala H, Salmi J, Oksala H, Jaatinen P. Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer. 2007;109:1972-9.The authors apologize for failing to cite reciprocally two recently published studies concerning long-term consequences after treatment of hyperthyroidism with radioactive iodine (RAI). In the first paper (Increased cancer incidence after radioiodine treatment for hyperthyroidism Cancer 2007;109:1972-9), we reported increased cancer incidence in patients treated with RAI compared with the ageand gender-matched controls; observed incidences of stomach, kidney, and breast cancer were increased among RAI-treated patients. In the second paper (Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab 2007;92:2190-6), we reported increased total mortality in these cohorts; this was largely explained by cerebrovascular disease, although increased mortality from all cancers and gastro-esophageal cancer was also reported. These data were complementary to each other, with one year's difference in the follow-up period.
Interrupted inferior vena cava (IVC) with azygous continuation to the superior vena cava (SVC) is a relatively common systemic venous anomaly. This anomaly can occasionally complicate transcatheter intervention by rendering more difficult the usual direct route to the systemic venous atrium afforded by femoral venous access. We report our experience with successful transcatheter closure of a large residual atrial septal defect (ASD) using the femoral venous route in a 3-year-old patient with heterotaxy syndrome of left isomerism type, dextrocardia, partial atrioventricular canal defect, and interrupted IVC with azygous continuation to the SVC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.